Clinical summary
Summary
This study has two phases: dose escalation and dose expansion. In the dose escalation phase, eligible participants will receive doses of [161 Tb]Tb PSMA I&T on Day 1 of every 6 week Cycle. The dose of [161 Tb]Tb PSMA I&T will vary, and will range between 4.4 GBq to 7.4 GBq. The recommended phase 2 dose (RP2D) of {161 Tb]Tb PSMA I&T will be used in the second phase, dose expansion. [161 Tb]Tb PSMA I&T dose will be reduced by 0.4 GBq for each subsequent cycle (2 to 6).Conditions
This trial is treating patients with metastatic castration-resistant prostate cancer.
Cancer
Urinary System
Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Peter MacCallum Cancer Centre
Scientific Title
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T: Phase I/II Study